ClinicalTrials.gg
CompletedNCT05360680Updated Jan 22, 2026

A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers

A Phase 1 interventional study of CUE-102 in Colorectal Cancer, Gastric Cancer and Pancreatic Cancer, sponsored by Cue Biopharma. Completed at 15 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-22.

Sponsored by Cue Biopharma · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Mar 2025, 1 year 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
42
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 2,342 studies in Colorectal Neoplasms with a site in United States — 415 open to participants now, 629 under way, 30 of them phase 3. Colorectal Neoplasms · United States.

Enrollment
1,191st of 1,934
42 · median 64
Started
2022
with 126 others
Phase 1
551 of 2,342
99 open now
Registered
1,745th of 2,342
by date

Among the 2,342 studies in Colorectal Neoplasms with a site in United States, this one is the 1,191st largest by enrollment of the 1,934 interventional ones that give a count, is one of 127 that started in 2022, is one of 551 in phase 1, and was the 1,745th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

415 of the 2,342 studies in Colorectal Neoplasms with a site in United States are open now. Recruiting first, the newest first:

410 more — sign in →

All 415 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,342 studies in Colorectal Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 1, open-label, 2-part, multi-center study evaluating the safety, tolerability, PK, pharmacodynamics (PD), immunogenicity, and antitumor activity of CUE-102 intravenous (IV) monotherapy in HLA-A*0201 positive patients with WT1 positive recurrent/metastatic solid tumors who have failed conventional therapies.

Read the detailed description

CUE-102 is a novel fusion protein developed for the treatment of patients with WT1-positive malignancies by selective engagement and expansion of tumor antigen-specific T cells that should allow for increased potential for anti-cancer efficacy and reduced toxicity relative to non-targeted forms of immunotherapy that result in systemic activation of the immune system.

The goal of Part A is to characterize the safety, tolerability, and biological effects of CUE-102.

The goal of Part B is to expand the safety and immune activity data at the RP2D identified in Part A, and to evaluate antitumor activity at this dose.

03

Conditions studied

  • Colorectal Cancer
  • Gastric Cancer
  • Pancreatic Cancer
  • Ovarian Cancer

Keywords

  • Wilms' tumor 1
  • HLA A*0201
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ability to provide and documentation of informed consent prior to initiation of any study-related tests or procedures that are not part of standard of care for the patient's disease.
  2. Age ≥18 years old
  3. (ECOG) performance status of 0 or 1
  4. ≥12 weeks
  5. as per 1.1 and documented by CT and/or MRI.
  6. All tumors must have or cytologically confirmed cancer diagnosis
  7. Patients must have any of the following cancers to be eligible:

    A. Colorectal cancer

    1. Histologically or cytologically documented adenocarcinoma of colon or rectum at the time of initial presentation
    2. or locally advanced/unresectable disease
    3. Documented disease progression after the last administration of standard therapies or intolerance to at least 2 prior systemic treatment regimens (CUE-102 will be therapy or greater).

    B. Gastric cancer (including gastroesophageal junction)

    1. Histologically or cytologically documented gastric cancer at the time of initial presentation
    2. Metastatic or locally advanced/unresectable disease
    3. Documented disease progression after last administration of standard therapies or intolerance to standard therapies. (CUE-102 will be 2nd line therapy or greater).

    C. Pancreatic cancer

    1. Histologically or cytologically documented pancreatic adenocarcinoma at the time of initial presentation
    2. Patients with metastatic or locally advanced/unresectable disease.
    3. Prior systemic treatment must include either a fluoropyrimidine-based or gemcitabine-based regimen in either the (neo) or setting. (CUE-102 will be 2nd line therapy or greater).

    D. Ovarian cancer

    1. Histologically or cytologically documented ovarian cancer at the time of initial presentation
    2. Metastatic or locally advanced/unresectable disease, with documented disease progression after last administration of standard therapies or intolerance to standard therapies.
    3. Prior systemic treatment must include a platinum-based regimen. (CUE-102 will be 2nd line therapy or greater).
    4. For patients determined to have platinum-sensitive disease, treatment with a second platinum-based combination regimen +/- bevacizumab should be considered prior to treatment with CUE-102 (CUE-102 will be 3rd line therapy or greater).
  8. Patient must have HLA-A*0201 genotype as determined by genomic testing.
  9. Patient must have histologically and/or cytologically proven tumor(s) that is WT1 positive.
  10. Acceptable laboratory parameters.
  11. Female patients of must agree to use acceptable measures from the time of main study consent through 90 days after discontinuation of study drug administration.
  12. Non-vasectomized male patients with partners of childbearing potential must use barrier contraception from the time of main study consent through 90 days after discontinuation of study drug.
  13. Patients who have previously received an immune CPI (e.g., anti-programmed cell death ligand 1 (anti ), anti-programmed cell death 1 (anti-PD-1), anti-cytotoxic T lymphocyte-associated antigen 4 [CTLA-4]) prior to enrollment must have toxicities related to the CPI resolved to ≤ Grade 1 or baseline (level prior to the CPI) to be eligible for enrollment. Patients who have experienced CPI-related endocrinopathies (e.g., diabetes, adrenal insufficiency) may participate if endocrinopathies are controlled (CTCAE ≤ Grade 1) with endocrinology support and appropriate repletion. Note: Patients who experienced previous hypothyroidism toxicity on a CPI are eligible to enter study regardless of CTCAE grade resolution as long as the patient is well controlled on thyroid replacement hormone.

Exclusion criteria

Exclusion Criteria:

  1. Female patients who are pregnant or plan to become pregnant during the course of the trial
  2. Female patients who are breastfeeding
  3. Patients with symptomatic central nervous system (CNS) must have been treated, be asymptomatic, and not have any of the following at the time of enrollment:

    1. Need for concurrent treatment for the CNS disease (e.g., surgery, radiation, >10 mg prednisone/day or equivalent)
    2. Progression of on CT or MRI for at least 28 days after last day of prior therapy for the CNS metastases
    3. Concurrent or cord compression.
  4. Has an active disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids, or drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is permitted.
  5. History of prior allogeneic bone marrow, stem-cell, or solid organ transplantation
  6. Treatment with any systemic anti-neoplastic therapy, or therapy within the 14 days (or 28 days, for antibody drugs), before the first dose of CUE-102.
  7. Treatment with radiation therapy within 14 days before the first dose of CUE-102
  8. Treatment with corticosteroids (> 10 mg per day prednisone or equivalent) or other immune suppressive drugs within 14 days before the first dose of CUE-102. Steroids for topical, ophthalmic, inhaled, or nasal administration are permitted. Physiological replacement with up to a maximum dose of 5 mg equivalence of prednisone per day is permitted.
  9. History of cardiovascular disease
  10. Clinically significant pulmonary compromise (e.g., requirement for supplemental oxygen)
  11. Clinically significant gastrointestinal (GI) disorders
  12. Patients who experienced the following immune CPI-related AEs are ineligible even if the AE resolved to ≤ Grade 1 or baseline:

    1. ≥ Grade 3 ocular AE
    2. Changes in liver function tests that met the criteria for Hy's Law (> 3× of either /AST with concurrent > 2× ULN of total (total and direct) and without alternate etiology)
    3. ≥ Grade 3 neurologic toxicity
    4. ≥ Grade 3 colitis
    5. ≥ Grade 3 renal toxicity
  13. Evidence of active viral, bacterial, or systemic fungal infection requiring parenteral treatment within 7 days before the first dose of CUE-102.
  14. No known history of infection or positive test for , or , testing prior to enrollment is not required unless mandated by local authority
  15. Second primary invasive that has not been in remission for > 2 years.
  16. History of trauma or major surgery within 28 days before the first dose of CUE-102
  17. Any serious underlying medical or psychiatric condition that would impair the ability of the patient to receive or tolerate the planned treatment at the investigational site
  18. Known to recombinant proteins, polysorbate 80 or any contained in the drug formulation for CUE-102
  19. Vaccination with any within 28 days before the first dose of CUE-102. Inactivated annual influenza vaccination is allowed.
  20. Dementia or altered mental status that would preclude understanding and rendering of
  21. Active or history of significant alcohol or other substance abuse within 1 year before the first dose of CUE-102
Terms in these criteria, in plain language(31)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    CUE-102 (1mg/kg) Dose Escalation

    CUE-102 (1 mg/kg) Monotherapy IV infusion every 3 weeks for up to 2 years

    Drug: CUE-102

  • Experimental
    CUE-102 (2 mg/kg) Dose Escalation

    CUE-102 (2 mg/kg) Monotherapy IV infusion every 3 weeks for up to 2 years

    Drug: CUE-102

  • Experimental
    CUE-102 (4 mg/kg) Dose Escalation

    CUE-102 (4 mg/kg) Monotherapy IV infusion every 3 weeks for up to 2 years

    Drug: CUE-102

  • Experimental
    CUE-102 (8 mg/kg) Dose Escalation

    CUE-102 (8 mg/kg) Monotherapy IV infusion every 3 weeks for up to 2 years

    Drug: CUE-102

  • Experimental
    CUE-102 Dose Expansion at Determined RP2D

    Dose expansion of CUE-102 at determined RP2D Monotherapy IV infusion every 3 weeks for up to 2 years

    Drug: CUE-102

Interventions

  • DrugCUE-102

    CUE-102 is a novel fusion protein developed for the treatment of patients with WT1-positive malignancies.

06

What researchers measure

Primary outcomes

  1. Dose Limiting Toxicity

    Evaluate dose-limiting toxicities (DLTs) during the first cycle of treatment with CUE-102, and to establish a recommended Phase 2 dose (RP2D)

    Time frame: 21 Days

  2. Maximum Tolerated Dose

    Evaluate maximum tolerated dose (MTD) to establish a recommended Phase 2 dose (RP2D)

    Time frame: 21 Days

  3. Serum PK AUC for CUE-102

    Area under the concentration-time curve (AUC) of CUE-102.

    Time frame: Up to 2 years

  4. Serum PK Cmax for CUE-102

    Maximum serum concentration (Cmax) of CUE-102.

    Time frame: Up to 2 years

  5. Serum PK T1/2 for CUE-102

    Terminal half-life (T1/2) of CUE-102.

    Time frame: Up to 2 years

Secondary outcomes

  1. Safety and Tolerability of CUE-102 Assessed by NCI CTCAE v5.0

    To evaluate safety and tolerability of CUE-102 using NCI CTCAE v5.0.

    Time frame: Up to 2 years

  2. Antitumor Response Rate with Treatment of CUE-102

    To evaluate antitumor response rate of CUE-102 by RECIST 1.1

    Time frame: Up to 2 years

  3. Antitumor Duration of Response with Treatment of CUE-102

    To evaluate antitumor duration of response of CUE-102 by RECIST 1.1

    Time frame: Up to 2 years

  4. Antitumor Clinical Benefit Rate with Treatment of CUE-102

    To evaluate antitumor clinical benefit rate of CUE-102 by RECIST 1.1

    Time frame: Up to 2 years

  5. Progression-Free Survival with Treatment of CUE-102

    To evaluate antitumor progression-free survival of CUE-102 by RECIST 1.1

    Time frame: Up to 2 years

  6. Overall Survival with Treatment of CUE-102

    To evaluate overall survival after treatment with CUE-102

    Time frame: From First CUE-102 to Date of Death

  7. Immune Response Assessed by WW1 Tetramer-Positive T cell Lymphocytes

    To evaluate the potential for immune response after treatment with CUE-102 using assessment of number of WT1 tetramer-positive T cell lymphocytes.

    Time frame: Up to 2 years

  8. Immune Response Assessed by CTL Markers of Activation

    To evaluate the potential for immune response after treatment with CUE-102 using assessment of cytotoxic T lymphocyte (CTL) markers of activation

    Time frame: Up to 2 years

07

Study locations

15 sites
  • Mayo Clinic
    Phoenix, Arizona 85054, United States
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
  • Stanford Advanced Medicine Cancer Center
    Palo Alto, California 94304, United States
  • Moffitt Cancer Center
    Tampa, Florida 33612, United States
  • Winship Cancer Institute
    Atlanta, Georgia 30322, United States
  • Johns Hopkins University
    Baltimore, Maryland 21231, United States
  • Mayo Clinic - Rochester
    Rochester, Minnesota 55905, United States
  • Carol G. Simon Cancer Center - Morristown Medical Center
    Morristown, New Jersey 07960, United States
  • Montefiore Medical Center
    The Bronx, New York 10461, United States
  • Carolina BioOncology Institute
    Huntersville, North Carolina 28078, United States
  • Gabrail Cancer Center
    Canton, Ohio 44718, United States
  • Cleveland Medical Center (University Hospitals)
    Cleveland, Ohio 44106, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Northwest Medical Specialties, PLLC
    Tacoma, Washington 98405, United States
  • Carbone Cancer Center
    Madison, Wisconsin 53792, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2022 to primary completion in Mar 2025, 32 months.

Of 269 industry-sponsored phase 1 interventional studies under Colorectal Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 66. This study's 32 months is below that.

Counting every sponsor, half of 435 studies reached it within 48 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2022
First posted
May 4, 2022
StartActual
Jun 14, 2022
Primary completionActual
Mar 12, 2025
CompletionActual
Mar 12, 2025
Last update
Jan 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05360680
Lead sponsor
Cue Biopharma
Responsible party
Sponsor
First posted
May 4, 2022
Start date
Jun 14, 2022
Primary completion
Mar 12, 2025
Completion
Mar 12, 2025
Last update
Jan 22, 2026

Study contacts

Matteo Levisetti, MD
study chair · Cue Biopharma

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion